Virologic response with 2 different cidofovir dosing regimens for preemptive treatment of adenovirus DNAemia in pediatric solid organ transplant recipients

Carlos H. Guerra Sanchez, Cherish D. Lorica, Kristopher Arheart, Michelle M. Perez, Akin Tekin, Ivan Gonzalez

Research output: Contribution to journalArticle

3 Scopus citations


ADV is frequently seen in our pediatric SOT population. It presents in a variety of clinical presentation and can cause severe disease. In this population, there are very few studies to determine the safety of CDV as a potential therapeutic agent. We present the findings of our retrospective study evaluating the efficacy and safety of CDV as 2 separate dosing regimens. Regimen A uses the standard 5 mg/kg once a week (Regimen A), and the second uses the 1 mg/kg 3 times per week (Regimen B). Overall, the dosing regimen did not differ in nephrotoxicity, but Regimen B had a higher, although non-significant, rate of viral load clearance. This suggests that more frequent dosing at lower levels may be more efficacious without any significant side effects in our SOT population.

Original languageEnglish (US)
Article numbere13231
JournalPediatric Transplantation
Issue number6
StatePublished - Jan 1 2018



  • Adenovirus
  • Cidofovir
  • Solid organ transplant
  • Viremia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Transplantation

Cite this